MedTrace Logo

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

NCT05188911 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-01-12

No results posted yet for this study

Summary

By incorporating dual-tracer PET/CT (PSMA and FDG) and ctDNA, we aimed to evaluate lesion heterogeneity and genomic change of mCRPC patients receiving novel hormonal therapy. The relationship between treatment response and different molecular characterization, as well as imaging features would also be evaluated.

Conditions

Interventions

DRUG

Abiraterone

Patients would be treated with 1000mg abiraterone qd.

DRUG

Prednisone

Patients would be treated with 5mg prednisone bid.

DRUG

Androgen deprivation therapy

Patients would get medical or surgical castration.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2022-07-15
Completion
2022-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05188911 on ClinicalTrials.gov